Thompson E J, Marwaha R, Naik G
Angiology. 1978 Mar;29(3):251-9. doi: 10.1177/000331977802900305.
In 13 patients admitted to a coronary care unit, antiarrhythmic efficacy and safety of quinidine gluconate in a nonmatrix formulation were compared to placebo and quinidine sulfate. Both quinidine preparations were effective in reducing the number and severity of ventricular and supraventricular extrasystoles when compared to placebo. Except for a few cases in which quinidine gluconate was significantly more effective, both quinidine preparations appear to have similar clinical antiarrhythmic efficacy and duration of action. A 24-hour Holter ECG monitoring device and electrocardioscanner were utilized in this research. No major unexpected adverse effects were observed.
在收治于冠心病监护病房的13例患者中,将非基质制剂葡萄糖酸奎尼丁的抗心律失常疗效及安全性与安慰剂和硫酸奎尼丁进行了比较。与安慰剂相比,两种奎尼丁制剂在减少室性及室上性期前收缩的数量和严重程度方面均有效。除少数葡萄糖酸奎尼丁明显更有效的病例外,两种奎尼丁制剂似乎具有相似的临床抗心律失常疗效和作用持续时间。本研究使用了24小时动态心电图监测设备和心电扫描仪。未观察到重大意外不良反应。